NCT01049295

Brief Summary

The aim of this study is to assess the effects of n-3 fatty acids on taxane-induced neuropathy and neurotoxic inflammatory agents in patients suffering from invasive breast cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
52

participants targeted

Target at P25-P50 for phase_4 breast-cancer

Timeline
Completed

Started Apr 2010

Shorter than P25 for phase_4 breast-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 13, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

January 14, 2010

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2010

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2012

Completed
Last Updated

November 1, 2011

Status Verified

April 1, 2011

Enrollment Period

1.6 years

First QC Date

January 13, 2010

Last Update Submit

October 29, 2011

Conditions

Keywords

taxanesbreast cancern3 fatty acidsinflammation

Outcome Measures

Primary Outcomes (1)

  • The EMG-NCV test,The serum level of IL-1,IL-6,TNF-alpha and hs-CRP

    first day and after 3 months (before chemotherapy with taxanes and at the end of the therapy

Secondary Outcomes (1)

  • The serum level of DHA and EPA fatty acids

    first day and after 3 months( before chemotherapy with taxanes and at the end of the therapy

Study Arms (2)

oil fish pearls

EXPERIMENTAL

patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day

Dietary Supplement: oil fish

placebo

PLACEBO COMPARATOR

patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day

Other: corn oil pearls

Interventions

oil fishDIETARY_SUPPLEMENT

Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day

oil fish pearls

corn oil pearls 3 times a day

placebo

Eligibility Criteria

Age30 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Suffering from invasive breast cancer,not receiving any form of supplementations and oil fish

You may not qualify if:

  • Suffering from the diseases leading to neuropathy, e.g.diabetes, hyperthyroidism, AIDS and primary neural diseases
  • Suffering from any other kind of malignancies
  • Receiving any chemotherapeutical agents in the past

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

: Tehran University of Medical Sciences, School of Public Health

Tehran, Tehran Province, Iran

RECRUITING

Related Publications (1)

  • Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, Hashemzade S, Asghari Jafarabadi M, Montazeri V, Keshavarz SA, Darabi M. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012 Aug 15;12:355. doi: 10.1186/1471-2407-12-355.

MeSH Terms

Conditions

Breast NeoplasmsInflammation

Interventions

Fish Oils

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

OilsLipids

Study Officials

  • Seyed Ali Keshavarz, professor

    Tehran University of Medical Sciences

    PRINCIPAL INVESTIGATOR
  • Zohreh Ghoreishi, Ph.D student

    Tehran University of Medical Sciences

    STUDY DIRECTOR

Central Study Contacts

Zohreh Ghoreishi, Ph.D student

CONTACT

seyed Ali Keshavarz, professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Master of Nutrition

Study Record Dates

First Submitted

January 13, 2010

First Posted

January 14, 2010

Study Start

April 1, 2010

Primary Completion

November 1, 2011

Study Completion

February 1, 2012

Last Updated

November 1, 2011

Record last verified: 2011-04

Locations